surrogate endpoint
A measurable stand-in (like blood pressure, cholesterol, or blood sugar) used in trials as a proxy for the clinical outcomes patients actually care about.
As defined in Adam Cifu on Ending Medical Reversal
Where it comes up · 6
- Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant6 claims
- Adam Cifu on Ending Medical Reversal3 claims
- Vinay Prasad on Pharmaceuticals, the FDA, and the Death of Duty3 claims
- Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]3 claims
- Vincent Rajkumar on the High Price of Cancer Drugs1 claim
- 98 - Into The Dark Land1 claim
Most important claims · 10 of 17Search all claims for “surrogate endpoint” →
- Surrogate endpoints (blood pressure, cholesterol, blood sugar) are cheap measurable stand-ins for clinical endpoints (how you feel, living longer, avoiding stroke), and therapies are often accepted because they improve the surrogate; but improving a surrogate does not guarantee improving the outcomes patients actually care about.Adam Cifu on Ending Medical Reversal
- The purpose of randomization in clinical trials is to seal doctors and patients from their own hopeful biases—not because doctors are malign but because they and patients badly want treatments to succeed and are drawn to solutions—and while crossover protocols and early-stopping rules have relaxed this somewhat, reliance on surrogate endpoints rather than survival has burned the field when shrinking tumors did not translate into longer life.98 - Into The Dark Land
- A surrogate is a biomarker such as tumor shrinkage that predicts clinical benefit, and validated surrogates let developers decide to continue or discontinue a drug in years rather than waiting five to ten years for survival outcomes, which is why government agencies should invest heavily in finding them.Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]
- Atenolol (marketed as Tenormin) lowers blood pressure as well as most other antihypertensives, but pooled placebo-controlled studies show it does not improve mortality or heart attack risk and only slightly reduces stroke risk, illustrating that a drug can succeed on the surrogate endpoint yet fail on clinical endpoints.Adam Cifu on Ending Medical Reversal
- By allowing studies without control arms, inadequate control arms, or surrogate endpoints like tumor shrinkage, the FDA creates a bar that is hard for small entrants to clear while making it easy to sustain lofty prices—producing a system that benefits large corporations and penalizes small entrepreneurs without guaranteeing the product works.Vinay Prasad on Pharmaceuticals, the FDA, and the Death of Duty
- Rather than blocking access, the FDA can reasonably approve a needed drug on surrogate-endpoint evidence, but it should require that studies of real clinical endpoints be ongoing at the time of approval; the problem is these confirmatory studies often never get done, leaving us using therapies that might not work.Adam Cifu on Ending Medical Reversal
- For a disease like multiple myeloma with 10-15 active drugs and 7-10 year median survival, drugs should not be approved on uncontrolled tumor-shrinkage studies; instead the bar should be improved survival over a real American standard of care, and ideally a clinically meaningful threshold (three to six months) that patients consider worthwhile.Vinay Prasad on Pharmaceuticals, the FDA, and the Death of Duty
- A drug can shrink a tumor without extending patient survival, exposing patients to toxicity while providing no benefit, so tumor shrinkage is an imperfect surrogate that can actually do net harm.Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]
- Melflufen, a 1960s drug with a small molecule added, was approved based on an uncontrolled myeloma study, then in a randomized trial against the weakest acceptable control arm showed no survival benefit with a hazard ratio trending toward harm—illustrating that taxpayer money paid for a drug that may have hurt patients relative to not having it at all.Vinay Prasad on Pharmaceuticals, the FDA, and the Death of Duty
- The cut-offs defining tumor 'response' (a 30%+ shrinkage in the sum of tumor diameters) derive not from evidence that they predict longer or better life, but from a 1970s Charles Moertel study in which 16 oncologists measured marbles through foam rubber with calipers; the cut-offs reflect the smallest change two oncologists could reliably discriminate and have simply been codified and passed forward through historical accident.Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant